Wane

Myeloid Therapeutics Rebrands as CREATE Medicines, Focused on Transforming Immunotherapy Through RNA-Based In Vivo Multi-Immune Programming

CREATE Medicines ("CREATE") broadens clinical programs and capabilities to expand therapeutic potential and improve patient outcomes Therapies tolerably program immune cells inside the human body, ...
eLife

Quantitative RNA pseudouridine landscape reveals dynamic modification patterns and evolutionary conservation across bacterial species

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, and public reviews. The manuscript by Xu et al. reported base-resolution mapping of ...
BioWorld

Arnatar emerges with RNA approach to both silence and restore

A few years after it was founded with the aim of taking RNA therapies to the next level, Arnatar Therapeutics Inc. emerged from stealth, disclosing a $52 million series A round raised in 2024 as well ...
BioSpace

AIRNA Presents Data Supporting RNA Editing Approach for Alpha-1 Antitrypsin Deficiency (AATD) at 28th ASGCT Annual Meeting

AIRNA is expected to file clinical trial application for optimized product candidate (AIR-001) with potential best-in-class profile for AATD in 2H 2025 CAMBRIDGE, Mass. &, TÜBINGEN, Germany--(BUSINESS ...
acm.org

GenDP: A Framework of Dynamic Programming Acceleration for Genome Sequencing Analysis

Genomics is playing an important role in transforming healthcare. Genetic data, however, is being produced at a rate that far outpaces Moore’s Law. Many efforts have been made to accelerate genomics ...